Archive


Category: CanSino Biologics

  • First published data backs CanSino’s inhaled COVID vaccine

    Early-stage clinical data with CanSino Biologics’ inhaled COVID-19 vaccine show that it was able to stimulate neutralising antibodies against SARS-CoV-2 at a dose well below that required with intramuscular administration. Published in The Lancet, a phase 1 study conducted in China showed that a two-dose regimen of aerosolised Ad5-nCoV was similar to that achieved with […]

  • ‘Promising’ data on Oxford/AZ, CanSino coronavirus vaccines

    Data from more than 1,000 healthy volunteers dosed with a coronavirus vaccine developed at Oxford University and AstraZeneca suggest the shot is safe and stimulates an immune response against the virus. The first phase 1/2 results with the ChAdOx1 vaccine – also known as AZD122 – were published today in medical journal The Lancet and […]